Just a year after J&J swooped in to buy up Aragon's game-changing work on prostate cancer in a billion-dollar deal, Roche's Genentech has followed up to buy what remained: a closely-related breast cancer program that promises to change the way that disease is treated.
Now that J&J has wrapped up the $1 billion acquisition of Aragon and its next-gen treatment for castration-resistant prostate cancer, the biotech's founders can devote themselves to a new startup that now has a $30 million venture bankroll to work with.
The deal gives J&J complete control over a combo approach with blockbuster potential that could help further improve the rapidly changing standard of care in prostate cancer.
The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the...
More than two years ago Oxford BioMedica put out the word that the FDA had cleared a Phase II study for its troubled program for TroVax, an immunotherapy to be tested in 80 patients suffering from hormone resistant prostate cancer. For Oxford, the mid-stage study was a key part of its comeback strategy for TroVax, which had already failed a study for renal cancer in 2008.
Now, more than ever, the life sciences industry is all about innovative and disruptive technologies. Every year for the past decade, FierceBiotech has made its picks on which companies hold the best odds for success in our Fierce 15 report. This year, though, we've added another Fierce 15 to focus on medical devices and diagnostics. I'd like to encourage readers to consider the differences by comparing the companies in each report.
Just days after reporting positive interim results from a mid-stage study of its closely-watched prostate cancer drug, San Diego-based Aragon Pharmaceuticals has topped up its bank account with a whopping $50 million venture round--bringing its total haul this year alone to $88 million.
Nick Leschly, the CEO of Bluebird Bio, playfully dubbed the ambitious spirit of biotechs Levin Syndrome, a fictional affliction named after Third Rock Ventures' Mark Levin that compels biotech entrepreneurs to, as they say, go big or go home. Our Fierce 15 companies are all "going big." They also went home… with trophies. Check out the slideshow below.
There's more than one way to build a biotech company. And this year's Fierce 15 companies reflect a range of companies operating with a spectrum of business models. Here's the full report >> Click here to view a video of FierceBiotech Editor John Carroll announcing the Fierce 15 at BioPharm America >>
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and Nesa Nourmohammadi (...